THERMOLIB: Efficiency of Lina LibrataTM System

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Recruiting
CT.gov ID
NCT03670680
Collaborator
(none)
38
1
1
60
0.6

Study Details

Study Description

Brief Summary

Menometrorrhagia is the first cause of consultation in gynecology. Etiology of menometrorrhagia is varied, but in majority of cases no underlying pathology is found, they are said functional idiopathic menometrorrhagia .

In case of failure of medical treatment, for women who do not wish to preserve reproduction possibilities, a surgical treatment by endometrectomy (destruction of the uterine endometrial epithelial) can be proposed. Currently, a new system, Lina LibrataTM is available on the market. This system allows destructing endometrial membrane with a balloon which offer several advantages compared to present used system. Specially, it does not require dilatation of uterus's cervix and it reduces the pain. The investigator make hypothesis that the use of the system Lina LibrataTM does not cause pain and can be thus used under local anesthetic in ambulatory surgery. With the aim of developing ambulatory care, the main objective of this prospective monocentric study is to estimate the efficiency of Lina LibrataTM system in the treatment of functional idiopathic menometrorrhagia. Secondary objectives are to estimate the pain during the procedure, the rate of per and post-complications and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Device: Use of the Lina LibrataTM
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
38 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Efficiency of Lina LibrataTM System in the Treatment of Functional Idiopathic Menometrorrhagia
Actual Study Start Date :
Oct 16, 2018
Anticipated Primary Completion Date :
Oct 16, 2022
Anticipated Study Completion Date :
Oct 16, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lina LibrataTM

Use of the Lina LibrataTM

Device: Use of the Lina LibrataTM
Use of the Lina LibrataTM

Outcome Measures

Primary Outcome Measures

  1. rate of amenorrhea [4 weeks]

Secondary Outcome Measures

  1. pain score [during surgery (Hour 0)]

    Pain at Hour 0 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain).

  2. pain score [2 hours after surgery (Hour 2)]

    Pain at Hour 2 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain).

  3. pain score [6 hours after surgery (Hour 6)]

    Pain at Hour 6 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine).

  4. pain score [6 hours after surgery (Hour 6)]

    Pain at Hour 6 1 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain)..

  5. pain score [the day after surgery (Day 1)]

    Pain at Day 1 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine).

  6. pain score [the day after surgery (Day 1)]

    Pain at Day 1 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain).

  7. pain score [one week after surgery (Day 7)]

    Pain at Day 7 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine)

  8. pain score [one week after surgery (Day 7)]

    Pain at Day 7 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain).

  9. pain score [one month after surgery (Month 1)]

    Pain at Month 1 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine)

  10. pain score [one month after surgery (Month 1)]

    Pain at Month 1 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain).

  11. recurrences of menorrhagia [at month 1]

  12. recurrences of menorrhagia [at month 6]

  13. assessment of menorrhagia on Higham's score [1 month after surgery]

    Assessment by patients on Higham's score. A score greater than 100 points corresponds to bleeding greater than 80 ml of blood.

  14. assessment of menorrhagia on Higham's score [6 months after surgery]

    Assessment by patients on Higham's score. A score greater than 100 points corresponds to bleeding greater than 80 ml of blood.

  15. evolution of hemoglobinemia [1 month after surgery]

    hemoglobin measured by blood test

  16. evolution of hemoglobinemia [6 months after surgery]

    hemoglobin measured by blood test

  17. per-operative complications [per surgery day 0]

  18. post-operative complications [post surgery day 0]

  19. measure of quality of life [at month 1]

    assessed by the questionnaire SF-12 (abridged version of the Medical Outcomes Study Short-Form General Health Survey SF-36). It allows to obtain 2 scores: mental and social score (from 5.89058 to 71.966825) and physical score (from 9.94738 to 70.02246). The average of this scores in the general population is 50.

  20. measure of quality of life [at month 6]

    assessed by the questionnaire SF-12 (abridged version of the Medical Outcomes Study Short-Form General Health Survey SF-36). It allows to obtain 2 scores: mental and social score (from 5.89058 to 71.966825) and physical score (from 9.94738 to 70.02246). The average of this scores in the general population is 50.

  21. measure of symptoms improvement [at month 1]

    assessed by the questionnaire PGI-I (from 1 "much better" to 7 "much worse")

  22. measure of symptoms improvement [at month 6]

    assessed by the questionnaire PGI-I (from 1 "much better" to 7 "much worse")

Eligibility Criteria

Criteria

Ages Eligible for Study:
38 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women from 40 to 50 years old

  • Not menopausal women

  • Do not want pregnancy

  • Having dysfunctional bleeding

  • informed and signed consent

Exclusion Criteria:
  • Unacceptable postoperative risk disclosed on interview: coagulation disorder, immune disorder, evolutive disease, etc

  • Pregnancy or wish to have later pregnancy

  • Endometrium cancer (or suspicious of cancer) or precancerous conditions of the endometrium

  • Anatomical conditions (i-e history of caesarian, transmural myomectomy) or pathological conditions (i-e long term treatment) which can weaken myometrium

  • Genital or urinary infection at the time of the procedure

  • Intra uterine device

  • Pelvic inflammation

  • Inability to understand information provided

  • Not covered by a national health insurance scheme, prisoner or under administrative supervision

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospices Civils de Lyon Bron France 69500

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

  • Principal Investigator: Géry LAMBLIN, MD, Hospices Civils de Lyon Gynaecology Department

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT03670680
Other Study ID Numbers:
  • 69HCL17_0266
  • 2017-A02017-46
First Posted:
Sep 13, 2018
Last Update Posted:
Mar 23, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 23, 2022